Start-Up Oncolytic Virus firm Trieza licenses Abzena antibody
Published on: genengnews.com, December 22, 2016
Source: GEN News Highlights
Trieza Therapeutics has negotiated an exclusive worldwide license, with sublicensing rights, to an antibody sequence generated using Abzena’s Composite Human Antibody™ technology. U.K.-based Abzena could receive up to $35 million in development and commercialization milestones, plus royalties on sales of licensed products containing the sequence. “This new license deal with Trieza provides the opportunity for Abzena to benefit from the commercialization of one of the assets originally developed by the Group to exemplify its proprietary antibody humanization and deimmunization technology,” commented John Burt, Ph.D., Abzena’s CEO. Abzena was formed as a group holding company in 2014 and incorporates the businesses of Antitope, PacificGMP, PolyTherics, The Chemistry Research Solution (TCRS), and Warwick Effect Polymers.